Kalydeco (kuh-LYE-deh-koh) will be added to the list of biotech drugs covered under the Reinsurance program for all Contractors effective 10/01/2012. Reimbursement will be 85% of the cost of the drug only for those members 6 years of age and older with evidence of the cystic fibrosis G551D mutation.

The Reinsurance Processing Manual will be updated to include Kalydeco as a biotech drug retroactive to October 1, 2012.

Contractors must submit medical documentation of the definitive lab results of the cystic fibrosis G551D mutation for all retroactive cases for dates of service effective from October 1, 2012, along with the “Request for Catastrophic Reinsurance Form Letter” located on the AHCCCS website at the following link: www.azahcccs.gov/commercial/ContractorResources/reinsurance/reinsurance.aspx to the AHCCCS Medical Management Unit by April 1, 2013.

Going forward, current procedures should be followed whereby the Contractors must make a formal request to the AHCCCS Medical Management Unit, include the supporting documentation and “Request for Catastrophic Reinsurance Form Letter” and coverage will be provided for a maximum 30 days retroactive from the date that notification was received by AHCCCS.

Valid NDC codes are as follows:

60-count bottle NDC 51167-200-02